<?xml version="1.0" encoding="UTF-8"?>
<p>It was suggested that the first model drug SN was active in stimulating the secretion of insulin, and the second drug DN prevented the absorption of filtered glucose from the kidneys and that excreted through urine. Therefore, the glucose was not reabsorbed into the blood causing high blood glucose levels. On the other hand, the presence of black seed extract (thymoquinone) in the combined representative F1-SNEDDS provided extra therapeutic properties in reducing blood glucose level (
 <xref ref-type="fig" rid="F0008">Figure 8</xref>) and in reducing insulin resistance.
</p>
